Farahnoosh Farnood

Dr. Farahnoosh Farnood


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2016 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Open access
YPYunes Panahi
Yunes Panahi
SDSimin Dashti-Khavidaki
Simin Dashti-Khavidaki
FFFarahnoosh Farnood
Farahnoosh Farnood
HNHamid Noshad
Hamid Noshad
MLMahsa Lotfi
Mahsa Lotfi
AGAfshin Gharekhani
Afshin Gharekhani
Therapeutic Effects of Omega-3 Fatty Acids on Chronic Kidney Disease-Associated Pruritus: a Literature Review

11 March 2025 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
YSYalda Rahbar Saadat
Yalda Rahbar Saadat
AAAmin Abbasi
Amin Abbasi
SHsina hejazian
sina hejazian
YHYalda Hekmatshoar
Yalda Hekmatshoar
MAmohammadreza ardalan
mohammadreza ardalan
SVSepideh Zununi Vahed
Sepideh Zununi Vahed
In 2008, the Society on Sarcopenia, Cachexia, and Wasting Disorders introduced a generic definition for all types of cachexia: “a complex metabolic syndrome associated with the underlying illness characterized by a loss of muscle, with or without fat loss”. It is well-known that the presence of inflammatory burden in end-stage renal disease (ESRD) patients may lead to the evolution of cachexia. Since the etiology of cachexia in chronic kidney disease (CKD) is multifactorial, thus the successful treatment must involve several concomitant measures (nutritional interventions, appetite stimulants, and anti-inflammatory pharmacologic agents) to provide integrated effective therapeutic modalities to combat causative factors and alleviate the outcomes of patients. Given the high mortality rate associated with cachexia, developing new therapeutic modalities are prerequisite for ameliorating patients with CKD worldwide. The present review aims to discuss some therapeutic strategies and provide an update on advances in nutritional approaches to counteract cachexia.

26 August 2022 in Inflammopharmacology
Verified
Journal Article
Closed access
PDF file
SHSeyyedeh Mina Hejazian
Seyyedeh Mina Hejazian
FFFarahnoosh Farnood
Farahnoosh Farnood
SASima Abedi Azar
Sima Abedi Azar

21 February 2019 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
KBKamal Boostani
Kamal Boostani
HNHamid Noshad
Hamid Noshad
FFFarahnoosh Farnood
Farahnoosh Farnood
HRHaleh Rezaee
Haleh Rezaee
STSoheil Teimouri
Soheil Teimouri
AGAfshin Gharekhani
Afshin Gharekhani
Introduction: Medication errors (MEs) are a leading cause of morbidity and mortality, yet they have remained as confusing and underappreciated concept. The complex pharmacotherapy in hospitalized patients and sometimes serious clinical consequences of MEs necessitate continued report and surveillance of MEs as well as persistent pharmaceutical care for patients at medical wards. This study evaluated the frequency, types, clinical significance, and costs of MEs in internal medicine wards. Method: In this 8-month prospective and cross-sectional study, an attending clinical pharmacist, as an integral member of a health care team, visited the patients during each physician's ward round at the morning. All MEs including prescription, transcription, and administration errors were detected, recorded, and subsequently appropriate corrective interventions were proposed during these rounds. The changes in the medications' cost after implementing clinical pharmacist's interventions were compared to the calculated medications' cost, assuming that the MEs would not have been detected by clinical pharmacist and continued up to discharge time of the patients. Results: 89% of the patients experienced at least one ME during their hospitalization. A mean of 2.6 errors per patient or 0.2 errors per ordered medication occurred in this study. More than 70% of MEs happened at the prescription stage by treating physicians. The most prevalent prescription errors were inappropriate drug selection, unauthorized drugs and untreated indication. The highest MEs occurred on cardiovascular agents followed by antibiotics, and vitamins, minerals, and electrolytes. Total number of MEs showed a marked correlation with the total number of ordered medications and patients’ length of hospitalization. The net effect of clinical pharmacist’s contributions in medication therapy management was to decline medications’ costs by 33.9%. None of the MEs caused the patients harm. Conclusion: The role of clinical pharmacy services in detection, prevention and reducing the cost of MEs is of paramount importance to internal medicine wards. Key words: clinical pharmacist; medication errors; pharmaceutical care; internal medicine.

1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
SHSeyyedeh Mina Hejazian
Seyyedeh Mina Hejazian
EAElham Ahmadian
Elham Ahmadian
SVSepideh Zununi Vahed
Sepideh Zununi Vahed
LGLeili Faraji Gogani
Leili Faraji Gogani
FFFarahnoosh Farnood
Farahnoosh Farnood
Background. To date, hemodialysis (HD) is the most common therapy for chronic kidney disease (CKD) patients. However, it causes different complications such as sleep disorders. Sleep regulation is connected to vitamin D; hence, its deficiency might influence the quality and duration of sleep. This study is aimed at evaluating the correlation of sleep quality and vitamin D levels in 80 HD patients. Methods. This cross‐sectional study was performed on 80 hemodialysis patients admitted to 29 Bahman hospitals in Tabriz, Iran. Before beginning of dialysis, serum 25 (OH) D levels were assessed among patients and the sleep patterns and sleep quality of patients were accurately calculated by the Pittsburgh sleep quality index (PSQI) standard questionnaire. Results. Our results showed that 22 HD patients (27.5%) had severe sleep disorders. In addition, it was found that serum levels of vitamin D had significant correlation with sleep quality (r = −0.341, p = 0.002) in general, even after adjusting confounding factors such as calcium (Ca), phosphate (P), and parathyroid hormone (PTH) level. In poor sleepers (PSQI ≤ 5), a negative correlation was observed between the levels of vitamin D and PSQI score (r = −0.397, p = 0.004). PSQI scores in the normal range of PTH (r = −0.377, p = 0.006) and in >600 pg/ml of PTH (r = −0.675, p = 0.011) had a correlation with vitamin D levels. The level of vitamin D was the single independent predictor of sleep efficiency (β coefficient = −0.386, p = 0.001). Conclusion. The present project reported that the positive effect of vitamin D is associated with sleep disorder in HD patients. In future studies, normal levels of Ca and P should be considered along with normal vitamin D levels among the included patients.

12 July 2021 in Advances in Therapy
Verified
Journal Article
Closed access
PDF file
SVSepideh Zununi Vahed
Sepideh Zununi Vahed
EAElham Ahmadian
Elham Ahmadian
SHSeyedeh Mina Hejazian
Seyedeh Mina Hejazian
SESaba Esmaeili
Saba Esmaeili
FFFarahnoosh Farnood
Farahnoosh Farnood